The antibiotic cefepime was linked to a slightly higher short-term all-cause mortality in a pooled analysis of 110 randomized trials involving more than 22,000 patients. The analysis found 6.6% mortality with cefepime versus 6.2% with other beta-lactams and estimated a 94.4% probability of higher risk (98.6% in 73 peer-reviewed trials). The signal was strongest in adults and in patients treated for febrile neutropenia. Researchers urge further study and clearer dosing guidance rather than stopping cefepime.
Major Analysis Links Cefepime to a Small Increase in Death Risk — Experts Call For Clearer Dosing Guidance
Cefepime is an antibiotic used to treat bacterial infections like pneumonia, UTIs and skin infections.
A widely used antibiotic, cefepime, has been associated with a small but measurable increase in short-term all-cause mortality in a new pooled analysis of randomized trials. The study pooled data from 110 randomized clinical trials that enrolled more than 22,000 patients treated with either cefepime or another beta-lactam antibiotic (the class that includes penicillins and cephalosporins).
Across the trials, 778 deaths occurred among 11,726 patients (6.6%) given cefepime versus a 6.2% death rate among patients treated with other beta-lactams. Investigators measured deaths from any cause occurring roughly within 30 days of treatment.
Across all trials, 778 deaths of any cause occurred among 11,726 patients (6.6%) given cefepime, compared to 6.2% of patients given another antibiotic.
Using a Bayesian meta-analysis, the authors estimated a 94.4% probability that cefepime is associated with higher all-cause mortality compared with other beta-lactams; when analyses were restricted to 73 peer-reviewed, published trials that probability rose to 98.6%.
The signal appeared stronger in adults than in children and was most pronounced among patients treated for febrile neutropenia (fever with dangerously low white blood cell counts). Despite the findings, the researchers did not recommend halting cefepime use, noting that the drug remains an important broad-spectrum option in hospitals because of its activity against many pathogens.
Finding the right dose of cefepime can be challenging, as higher doses may improve the drug's ability to kill bacteria but also increase the risk of toxic side effects.
Possible Explanations and Clinical Context
Investigators suggested several potential explanations for the observed association but were unable to identify a single causal mechanism. Possible factors include subtherapeutic drug levels that fail to control infection, neurotoxic effects at high serum concentrations (which can cause confusion, reduced consciousness, or seizures), and variability in dosing strategies across trials. Older adults and patients with impaired kidney function are known to be at higher risk for cefepime-related neurotoxicity, according to clinical references such as the Mayo Clinic.
Dr. Marc Siegel, a senior medical analyst not involved in the study, noted that febrile neutropenia itself is a major driver of mortality in affected patients and that both underdosing and overdosing of cefepime could contribute to poorer outcomes. He also suggested that tools such as artificial intelligence might help tailor optimal dosing for individual patients.
Limitations And Recommendations
The meta-analysis combined trials that varied in design, patient populations, dosing regimens, comparator antibiotics and era (some studies date back decades). These differences limit certainty and mean the results show an association, not proof that cefepime itself caused the higher mortality.
The study authors called for additional research and clearer dosing guidance rather than immediate discontinuation of cefepime. Clinicians should weigh potential risks and benefits when selecting therapy and adjust dosing for renal function and clinical context. Patients with concerns should discuss them with their healthcare providers.
Help us improve.
